BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 11283848)

  • 1. The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model.
    Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Ikenaka Y; Noguchi R; Nakatani T; Tsujinoue H; Fukui H
    Hepatology; 2001 Apr; 33(4):841-7. PubMed ID: 11283848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
    Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
    Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
    Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
    Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody.
    Luo JC; Toyoda M; Shibuya M
    Cancer Res; 1998 Jun; 58(12):2594-600. PubMed ID: 9635584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.
    Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Hicklin DJ; Huber J; Nakatani T; Tsujinoue H; Yanase K; Imazu H; Fukui H
    Hepatology; 2002 Apr; 35(4):834-42. PubMed ID: 11915029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma.
    Ng IO; Poon RT; Lee JM; Fan ST; Ng M; Tso WK
    Am J Clin Pathol; 2001 Dec; 116(6):838-45. PubMed ID: 11764072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1).
    Yamane A; Seetharam L; Yamaguchi S; Gotoh N; Takahashi T; Neufeld G; Shibuya M
    Oncogene; 1994 Sep; 9(9):2683-90. PubMed ID: 8058332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma.
    Fine BA; Valente PT; Feinstein GI; Dey T
    Gynecol Oncol; 2000 Jan; 76(1):33-9. PubMed ID: 10620438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts.
    Takahashi T; Shibuya M
    Oncogene; 1997 May; 14(17):2079-89. PubMed ID: 9160888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.
    Zhu Z; Rockwell P; Lu D; Kotanides H; Pytowski B; Hicklin DJ; Bohlen P; Witte L
    Cancer Res; 1998 Aug; 58(15):3209-14. PubMed ID: 9699643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
    Joukov V; Pajusola K; Kaipainen A; Chilov D; Lahtinen I; Kukk E; Saksela O; Kalkkinen N; Alitalo K
    EMBO J; 1996 Jan; 15(2):290-98. PubMed ID: 8617204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium.
    Mukhopadhyay D; Nagy JA; Manseau EJ; Dvorak HF
    Cancer Res; 1998 Mar; 58(6):1278-84. PubMed ID: 9515816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells.
    Takahashi T; Yamaguchi S; Chida K; Shibuya M
    EMBO J; 2001 Jun; 20(11):2768-78. PubMed ID: 11387210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developmental expression of vascular endothelial growth factor (VEGF) receptors and VEGF binding in ovine placenta and fetal membranes.
    Bogic LV; Brace RA; Cheung CY
    Placenta; 2001 Apr; 22(4):265-75. PubMed ID: 11286562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma.
    Strizzi L; Catalano A; Vianale G; Orecchia S; Casalini A; Tassi G; Puntoni R; Mutti L; Procopio A
    J Pathol; 2001 Apr; 193(4):468-75. PubMed ID: 11276005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The angiogenic pathway "vascular endothelial growth factor/flk-1(KDR)-receptor" in rheumatoid arthritis and osteoarthritis.
    Giatromanolaki A; Sivridis E; Athanassou N; Zois E; Thorpe PE; Brekken RA; Gatter KC; Harris AL; Koukourakis IM; Koukourakis MI
    J Pathol; 2001 May; 194(1):101-8. PubMed ID: 11329148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flk-1 as a target for tumor growth inhibition.
    Strawn LM; McMahon G; App H; Schreck R; Kuchler WR; Longhi MP; Hui TH; Tang C; Levitzki A; Gazit A; Chen I; Keri G; Orfi L; Risau W; Flamme I; Ullrich A; Hirth KP; Shawver LK
    Cancer Res; 1996 Aug; 56(15):3540-5. PubMed ID: 8758924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of KDR/Flk-1 (VEGFR-2) in murine model of ischemia-induced retinal neovascularization.
    Suzuma K; Takagi H; Otani A; Suzuma I; Honda Y
    Microvasc Res; 1998 Nov; 56(3):183-91. PubMed ID: 9828156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.